Precision engineering maker of crushing/screening equipment with no listed Indian peer, 20-country dealer base and capacity to triple revenue, available at modest forward valuations; offset by cashflow strain, repeated dilution and management grey flags.

Precision engineering maker of crushing, screening and washing equipment has no listed Indian peer, industry growth of 30-35% and guided 40-50% FY27 growth, but carries working-capital, dilution and governance/communication concerns.

ISGEC's core engineering business is inflecting: shorter, better-priced contracts, higher export mix, improving project margins and lower borrowing, while the loss-making Philippines ethanol plant drags on group profits and depresses the stock after five flat years.

Altius remains the largest holding because its InvIT structure offers an attractive ~9% cash yield, providing income even as the portfolio becomes less defensive.

Investor is taking more risk by rotating from defensive REIT/InvIT holdings into inflection-point stocks; new eight positions are 8.6% of portfolio as additions, not core replacements.

Railway ancillary with a large Railways capex opportunity (Vande Bharat interiors, refurbishment) but execution lags guidance; the defence/aerospace JV with a pre-revenue partner is high-risk. Watch receivables collection, order-book delivery and a likely capital raise.

E-commerce players that control their own logistics and payments processing gain a durable competitive edge, and this combination will disrupt traditional banks' underwriting business.

Shift from low-margin railway system integrator to high-margin OEM product maker via subsidiary Nova Control for Kavach train protection, offering in-house tech plus on-ground execution under one roof.

e2e is shifting from a low-margin railway system integrator to a higher-margin OEM play by making Kavach/Train Protection products in-house via subsidiary Nova Control Technologies, combining product tech with site execution where peers do only one.

Valiant Organics shows a real operating recovery: pharma and specialty profits improved, and the new Saykha plant is contributing via its Laboratories stake. However, cash conversion is unproven and China/input-cost risks mean valuation discipline is still required.

ESDS committed to buy ~$1.25B of GPU capacity from SharonAI, but profit depends on a matching onward contract and timely payments. The customer advance helps, but the commercial bridge and termination risks remain unverified.

A genuinely good rental business with 25% ROCE and strong cohorts, but the IPO is priced at ~62x adjusted FY26 PAT; aggressive depreciation-life extensions and unresolved co-founder litigation make the price fail the test. Avoid the issue, wait for listing dip.

Balu Forge has proven it can build world-class forging and machining capability, win NATO, aerospace and railway orders, and ride three stacked tailwinds; what remains unproven is whether that capability converts into actual cash flow.

Apollo Cash's D2C pivot is compelling because Apollo now owns customer, underwriting and repayment data, and early adoption and credit signals are encouraging — but mature profitability after credit losses and collection costs remains unproven, so risk sits closer to shareholders.

Strong retail growth without a legacy brand shows differentiated product and marketing; new Surat and Rajkot stores should lift the higher-margin retail mix and improve profitability and returns.

Forbes shows an early operating inflection: installed capacity is converting an old strategy into faster earnings amid a strong cutting-tools upcycle, but market-share gains are unproven. At ₹137.95 it merits watchlist status only, not a no-brainer.

Forbes is a special-situation asset monetisation play: its stake in Svadeshi Mills gives exposure to ~48 acres in Mumbai, and the Bombay High Court revival ruling creates a path to redevelopment. At ~₹302/share vs an SOTP NAV of ~₹1,049/share, the market is pricing in a large discount to potential asset value.

The profit surge reflects exiting loss-making Polish die-casting, while electrical instruments grow strongly; consolidated stagnation masks these divergent moves. Poor cumulative free cash flow from heavy capex and a ~33x multiple mean the stock's risk/reward depends on capex returns and takeover speculation.

E2E wants to become the platform enterprises run their AI on, not just a GPU renter — integrating infrastructure, software and model tools to build switching costs and more recurring inference/agentic workloads, justifying large capex ahead of demand.

TeamLease, at 12.9x reported P/E, may be a temporarily depressed margin story: better contract pricing, specialised staffing and lower recruiting costs should drive a meaningful margin recovery by FY30, though Q1 FY27 may not be the bottom.

Record banking surplus from RBI's FCNR(B) dollar swap, combined with strong credit demand, could leave India in a comfortable liquidity environment if RBI absorbs only part of the surplus; aggressive sterilisation would make the episode short-lived.

Epigral's capacity doubling in CPVC and epichlorohydrin may not deliver expected profits because new competitors are building for the same demand, so the stock is not compelling at roughly 20x earnings.

MIDHANI is a near-monopoly advanced alloy maker vital to India's aerospace, defence, space and nuclear programmes. Its falling margin is really a down payment for future growth, and a new jet-engine maker certification is an underappreciated catalyst.

Many sectors and stocks have run up, so the next 2-3 years will favour selective stock pickers and rotation into remaining deep-value pockets; avoid low-PE/depreciation-heavy names because they can be value traps.

Zudio's store-level unit economics already proved repeatable before consolidated profits showed it: mature stores crossed ₹14,000 sales per square foot, required low capital, and grew without advertising. The market's old model of Trent's P&L left this inflection underpriced.

IVP may be moving structurally from low-margin foundry chemicals to higher-margin PU/speciality adhesives; if margins stay near 9-10%, its earnings profile could improve materially, though receivables and cash conversion remain risks.

HDFC Bank at ₹701 is not pricing collapse, only a gradual recovery to 15–16% ROE; NIM normalization and deposit-mix repair are key levers, so it is a decent long-term compounder but not an obvious bargain.

Indus Towers is the cleaner way to play Vodafone Idea's recovery: it earns tower rent without the operator's balance-sheet risk, though at ₹375 it is fairly valued rather than cheap, with a low tenancy ratio.

Despite early operating recovery and rising ARPU, equity at ₹14 is a poor risk/reward because it trades at ~37x EV/cash EBITDA with huge statutory dues, leases, and dilution risk; even tripling EBITDA barely justifies the price.

Tiny Puducherry landlord/lender: rent, loan interest and solar income support a ~5.6% dividend yield, and the commercial property may be worth close to the ~₹37 crore market cap, leaving the ₹6.9 crore loan book and solar assets nearly free if property value holds. The main risk is the rolled-over ₹6.9 crore loan book to unidentified borrowers; it generates ~49% of PAT, and even a 20% impairment would wipe out roughly three-quarters of FY26 profit. Disclosure on leases, tenants, property valuation and rising voluntary donations is weak, so this is a yield/asset-value situation with meaningful governance and credit uncertainty, not a growth story.

Change of control to GRT is a credible unlock, but the operating turnaround is unproven. At the current price, the market has priced in much of the improvement before GRT has demonstrated sustainable growth, so watch rather than chase.

The bet is a strategic pivot to asset-light Ayurvedic infertility hospitals, using an existing digital patient funnel and in-house pharma margins to scale bed count and revenue rapidly, though execution and customer-acquisition costs pose risks.

Satkartar's pivot from D2C Ayurveda to asset-light infertility-focused hospitals can unlock operating leverage; its digital patient funnel and trained call-center infrastructure should drive occupancy and high-margin revenue as bed capacity scales.

A tyre recycler benefiting from formalisation, EPR credits and rising demand for value-added recycled rubber, with a modest moat. The business is improving, but at ₹996 the stock already prices Vision 2029 and future growth, making it unattractive now.

India's electricity and water demand should rise structurally from data centres, industry, EVs and agriculture, creating long-duration opportunities in nuclear capacity, water treatment, recycling and infrastructure.

Dhoot's dominant 41% share in 2W/3W wiring harnesses, in-house components, and EV/ABS content growth drive durable growth; however, high valuation prices in uncertain adjacent businesses and limits to further share gains.

Integrated nuts processor and ice cream maker expects ~50% revenue and profit growth, backed by capacity expansion, rising freezer network, GST tailwind, and regional headroom; execution and working capital are key risks.

Shanti Gold is positioned for strong growth as a scaled, newly listed B2B jewellery manufacturer: capacity is expanding, it guides 50-60% revenue growth for three years, and targets 7.5-8% EBITDA margin; execution and working-capital/cash-flow risks remain.

The falling rupee added roughly ₹2,213 crore to FY26 revenue for 15 CDMO/specialty-chemical exporters, inflating reported export growth by about 4.8 percentage points. This is a currency windfall rather than real volume growth, so reported earnings quality is weaker than it appears.

Sarthak has a genuine niche in cored-wire consumables, but its financial record shows no durable pricing power or moat: revenue, margins and ROCE collapsed. Working-capital deterioration, a promoter-related loan and low-quality book value make it uninvestable despite the cheap multiple.

Reported profit likely overstates owner earnings because development spending is capitalised rather than expensed, while operating cash flow lagged fixed-asset purchases. The apparent cheap SaaS valuation is therefore misleading.

It looks statistically cheap with strong ROCE and low debt, but one customer supplied 99.763% of FY26 revenue, making it effectively a captive supplier with unacceptable customer-concentration risk.

The Agarwal family's two-decade capital-allocation discipline, avoiding debt and never posting a loss, lets it safely fund an ₹18,000 crore expansion without borrowing—turning cyclical steel risk into compounding growth.

E2E's visible future growth—possibly ₹1,000 crore revenue by FY27—may still not be reflected in the price, so fair value can still be attractive without a contrarian angle.

Record FII outflows have likely bottomed; with two months of net buying, a US tariff truce, and a weaker dollar, foreign capital should return gradually and unevenly, though DII dominance and structural risks cap the rebound.

The company could benefit from value-added stainless products and new seamless-plant capacity; a Goldman stake, low debt and positive cash flow improve the risk-reward, though raw material is outsourced.

Avoid ESDS IPO: reported profit and cash flow are inflated by SPOCHUB's one-off 63.5% margin, a ₹1,176 crore customer advance, and concentrated overseas customers replacing a sanctioned Russian account; weak disclosures and governance make the valuation unjustified.

A dominant power exchange with excellent economics but regulatory market coupling and possible fee cuts threaten its network-effect moat; at ₹124 the downside outweighs upside, with intrinsic value near ₹89.

Credible pharma intermediates/CDMO and semiconductor materials story, but at ~61x FY27 earnings the market already prices exceptional execution; Indichem's optionality does not justify buying at ₹3,300.

Sambhv's full backward integration from iron ore to pipes gives it a low-cost, high-quality position with premium pricing, helping it earn 19% returns, grow profits sharply, and triple capacity while still being priced like a commodity maker.